HIV / AIDS

The committee voted 16 to 2 to recommend F/TAF for PrEP based upon data from the phase 3 DISCOVER study, which evaluated F/TAF in comparison with F/TDF.

A novel NNRTI hits the market, but what place will it have in treatment?

Some rural counties with historically low rates of HIV infection are now experiencing increased risks for HIV transmission of the virus and do not have the infrastructure or resources to respond appropriately.

Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.

The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.

Providers’ communication styles and level of knowledge about HIV have a significant impact on whether patients begin and remain in treatment.

At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.

The final results of HOPE, a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence.

The discovery of dendritic cells known as CD11c+ offers a pathway to understanding the mechanism behind HIV transmission and how to halt it.

New results indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA > 50 copies per mL at week 48.

The investigators observed durable humoral immune responses over 2 years with a response rate of 100% in participants receiving the Ad26.Mos.HIV, gp140HD vaccine regimen.

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

The phase 2a study compares a bivalent combination of Clade C and Mosaic gp140 with a single-valent Clade C gp140.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.

Two phase 3 studies presented at IAS 2019 evaluated a switch to B/F/TAF among individuals virologically suppressed on other HIV treatment regimens.

A handful of new studies weighing the risks and benefits of ART regimens containing dolutegravir have triggered new recommendations from the WHO.

The team assessed program engagement, medication refills, and self-reported 3-day adherence over 72 weeks, among the individuals who initiated PrEP.

The difference between NTD prevalence with dolutegravir and non-dolutegravir antiretrovirals from conception was small, but significant at 0.20% difference (95%CI 0.01%, 0.59%).

Global HIV/AIDS data from 2018 reveals that some countries are making tremendous strides towards the 2020 targets, while others are still seeing a rise in new HIV cases and AIDS-related deaths.

Investigators detected HIV DNA in the cerebrospinal fluid of 48% of participants, which was linked to worse neurocognitive outcomes.

The guidelines include a new section featuring recommendations for treating transgender people living with HIV.

Mosaico plans to register 3800 HIV-negative participants aged 18 to 60 years when enrollment opens later this year.

Long-acting reservoir-style PrEP implants could help solve adherence issues.

PrEP awareness among these MSM rose from 60% to 90% from 2014 to 2017, and PrEP use increased from 6% to 35%.

New research assesses potential alternatives to a daily dose of emtricitabine/tenofovir. It finds mixed results.